CTU: A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05)

  • Sabanathan, Dhanusha (Primary Chief Investigator)
  • Chester, Catherine (Clinical Trial Unit Staff)
  • Chapman, Nicola (Clinical Trial Unit Staff)

Project: Research

Project Details

Short titleSGNTUC-028
Effective start/end date4/08/2223/02/27